Published in Physician Law Weekly, January 17th, 2007
The PBT2-201-Euro trial is being conducted in seven centers throughout Sweden and will focus on exploring the safety and tolerability of PBT2, Prana's proprietary lead compound, and its effects on the mechanism and progression of the disease, investigating both central and peripheral biomarkers of Alzheimer disease as well as cognition.
The principal investigator for the trial is Professor Lars Lannfelt, MD, PhD, of the department of Public Health/Geriatrics at Uppsala University. Lannfelt and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.